Sign inJoin waitlistJoin the waitlist

JS

Jason Suh

Clinical Assistant Professor, The Icahn School of Medicine at Mount Sinai · Icahn School of Medicine at Mount Sinai

Credentials: · · · · · ·

History

Icahn School of Medicine at Mount Sinai
Present
Icahn School of Medicine at Mount Sinai
Present

Hematology and Medical Oncology
NYU Grossman Long Island School of Medicine
2010–2013
Internal Medicine
NYU Grossman Long Island School of Medicine
2007–2010
Saint George's University School of Medicine
2003–2007

Research

A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis
BMC Neuroscience · 2006 · 227 citations
Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity
Journal of Biological Chemistry · 2003 · 99 citations
A role of P301L tau mutant in anti-apoptotic gene expression, cell cycle and apoptosis
Molecular and cellular neurosciences · 2003 · 28 citations

Alexander Hindenburg
3 papers
AM
Anusiyanthan Mariampillai
2 papers · 2 as a fellow
PP
Patrick Pompl
2 papers
Abirami Sivapiragasam
1 paper · 1 as a fellow
AY
Amy Yeung
1 paper · 1 as a resident
AD
Andrei Dobrescu
1 paper
Anish Desai
1 paper · 1 as a fellow
DL
Dale Lange
1 paper
Jonathan Haas
1 paper
MT
Metin Taskin
1 paper
SC
Sita Chokhavatia
1 paper
SS
Steven Shayani
1 paper

Clinical trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029